(Q34720380)

4 August 2017

title

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine (English)

1 reference

4 August 2017

9

Hanne Nøkleby

1 reference

4 August 2017

3

Philipp Oster

1 reference

4 August 2017

10

Ingeborg S Aaberge

1 reference

4 August 2017

7

Einar Rosenqvist

1 reference

4 August 2017

1

Berit Feiring

1 reference

4 August 2017

5

Oddveig S Helland

1 reference

4 August 2017

6

Sandrine Tilman

1 reference

4 August 2017

4

Lisbeth M Naess

1 reference

4 August 2017

Jan Fuglesang

2

1 reference

4 August 2017

Marianne A R Bergsaker

series ordinal

8

1 reference

4 August 2017

publication date

1 July 2006

1 reference

Clinical and Vaccine Immunology

4 August 2017

published in

1 reference

4 August 2017

volume

13

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

790-796

1 reference

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Meningococcal surrogates of protection--serum bactericidal antibody activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Vaccine prevention of meningococcal disease, coming soon?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Population genetics and molecular epidemiology of Neisseria meningitidis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

The epidemiology of meningococcal disease in Norway 1975-91

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1489568

Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine

26 October 2018

1 reference

12 December 2020

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile

1 reference

12 December 2020

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

12 December 2020

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

12 December 2020

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

12 December 2020

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

12 December 2020

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

1 reference

12 December 2020

Identifiers

DOI

10.1128/CVI.00047-06

1 reference

4 August 2017

1 reference

4 August 2017

1 reference